Clinical Trials Browser

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT00494442 2018-08-01

ICEBERG 2

Phase 2 Completed

58 enrolled 13 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT01339650 2018-01-02

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Completed

93 enrolled

Classical hematology

Fanconi Anemia, Complementation Group D1

NCT02959398 2017-11-24

ETOLE

Phase NA Unknown

2,000 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00419510 2016-08-17

Genetic Counseling in African American Women

Phase NA Completed

204 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01346761 2016-04-14

REACH

Phase NA Completed

1,012 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms, Genetic Predisposition to Disease

NCT00413491 2014-05-20

MR BRCA

Phase 4 Unknown

300 enrolled

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00677079 2013-10-01

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

12 enrolled

Classical hematology

Fanconi Anemia, Complementation Group D1

NCT01772979 2013-01-21

MITO15

Phase 2 Unknown

100 enrolled

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00165152 2012-08-09

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Phase NA Completed

150 enrolled

BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

Clinical Trials

Olaparib In Metastatic Breast Cancer

COBRA

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

ICEBERG 1

LUSTIC

Methods in Education for Breast Cancer Genetics

ICEBERG 3

REVIVAL

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

ICEBERG 2

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

ETOLE

Genetic Counseling in African American Women

REACH

MR BRCA

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

MITO15

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing